Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) announced that GENSCI Singapore, a wholly-owned subsidiary of the company's holding subsidiary Jinsai Pharmaceutical, and Baosheng Pharmaceutical intend to sign an “Asset Sale Agreement” and “Supply Agreement”. Baosheng Pharmaceutical will transfer the intellectual property rights (including trademarks, etc.) of the pharmaceutical marketing license holder (MAH) held by Baosheng Pharmaceutical (“Meshia®”) worldwide other than Hungary (“scope region”) exclusive to this product SCI Singapore At the same time, GENSCI Singapore authorized Baosheng Pharmaceutical to manufacture and supply this product for a long time.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) announced that GENSCI Singapore, a wholly-owned subsidiary of the company's holding subsidiary Jinsai Pharmaceutical, and Baosheng Pharmaceutical intend to sign an “Asset Sale Agreement” and “Supply Agreement”. Baosheng Pharmaceutical will transfer the intellectual property rights (including trademarks, etc.) of the pharmaceutical marketing license holder (MAH) held by Baosheng Pharmaceutical (“Meshia®”) worldwide other than Hungary (“scope region”) exclusive to this product SCI Singapore At the same time, GENSCI Singapore authorized Baosheng Pharmaceutical to manufacture and supply this product for a long time.